12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RG7685: Development discontinued

In its 3Q12 earnings, Roche said that it discontinued development of RG7685, which was in Phase I testing for...

Read the full 75 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >